EndoGastric funds US sales with $30m round:
This article was originally published in Clinica
Executive Summary
Natural orifice surgery (NOS) specialist EndoGastric Solutions has completed a $30m series D round of financing. Redmond, Washington-based EndoGastric plans to use the new finances to expand sales and marketing efforts for its transoral StomaphyX device for binding tissue in the gastrointestinal tract to help weight loss, and fund the launch of its EsophyX device for treating gastroesophageal reflex disease later this year. The round was lead by DeNovo Ventures and included contributions from existing investors Chicago Growth Partners, MPM Capital, Advanced Technology Ventures, Foundation Medical Partners and Oakwood Medical Investors. The financing sees DeNovo's Joe Mandato join the EndoGastric board of directors.
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.